Statins are a well characterised class of medication that are used to lower cholesterol levels in the body. There is considerable evidence supporting the repurposing of certain statins for use as a potential treatment for Parkinson's, and this particularly applies to a statin called simvastatin. Read more about this here

The neuroprotective potential of statins received further support from a new study of progressive supranuclear palsy or PSP, which is a condition very similar to Parkinson's. In this study, the researchers found that statin use reduces the risk of PSP and may also delay the onset of symptoms.

The study is based on only a small population of several hundred individuals with the condition, who were matched with a similar number of control subjects. The finding requires carefully controlled independent replication, but if repeated, the association would provide strong support for repurposing statins for neurodegenerative conditions like PSP and Parkinson's. They may also offer some insights into the mechanisms underlying these diseases.

The Cure Parkinson's Trust - in collaboration with Van Andel Institute and JP Moulton Charitable Foundation - has been supporting the PD-STAT clinical trial in the UK, which has been investigating simvastatin as a potentially disease modifying therapy for Parkinson's. The study is scheduled to finish this year. Read more about this study.

Read more about the simvastatin trial

Read more about the PD-STAT protocol